The development of aggressive lymphoma, typically DLBCL, in patients initially diagnosed with CLL is the defining characteristic of Richter transformation.
A review of case studies that outline treatment decisions based on patient and disease characteristics.
Rituximab has some single-agent activity in HCL, but there is evidence that it may eliminate MRD when used with cladribine or pentostatin.
The new type of adoptive cell therapy showed a response in 8 of 11 patients with hematologic malignancies in a clinical study.
Researchers sought to determine whether second cancers associated with MPNs affect a patient’s prognosis, and whether cytoreductive or antiplatelet therapies affect outcomes.
Due to the possibility of loss of CD19 expression following treatment with a single CD19-targeted approach, patients may become ineligible for the alternative approach.
The best bet for a new company hoping to deliver on a lofty promise to “remake medicine” could rely on drug repurposing.
The researchers found that high rates of remission could be achieved with induction therapy using rituximab/bendamustine in addition to rituximab/cytarabine.
A retrospective analysis found encouraging evidence for the use of BvB in treatment of RR-cHL.
Researchers conducted a meta-analysis of 7 studies involving NHL and 3 focused on MM to determine the role of occupational exposure to glyphosate in terms of risk.
The authors of this article emphasized the importance of actively involving a diverse group of interdisciplinary team members in the psychosocial care of these patients.
Researchers use whole-genome and whole-transcriptome sequencing data to reveal viral sequences in cancer tissue.
One finding from this study was that VTE was more likely to occur at atypical sites in patients with myelofibrosis compared to those without the disease.
In this study, epigenetic heterogeneity was not associated with the birth rate of leukemic cells.
Screening patients by phone before they come to a clinic may help to eliminate potentially redundant visits and lower the risk of infection.
Increased risk particularly seen with keratinocyte cancer and lymphomas.
This study investigated differences in the morbidity and mortality of patients presenting with PV or ET with and without splanchnic vein thrombosis.
A federal ruling will force trial sponsors to post basic results on ClinicalTrials.gov, but it is unclear whether this is a feasible mandate.
A study showed how long patients with CLL may live after CAR-T therapy failure, providing a benchmark for trials evaluating therapies in the post–CAR-T setting.
CRISPR-modified T cells were used in 3 patients with advanced cancer for the first time, showing modest results on tumor growth.